TransMedics Group’s (NASDAQ:TMDX) quiet period is set to end on Tuesday, June 11th. TransMedics Group had issued 5,690,000 shares in its public offering on May 2nd. The total size of the offering was $91,040,000 based on an initial share price of $16.00. During the company’s quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
TMDX has been the topic of several research analyst reports. Cowen initiated coverage on shares of TransMedics Group in a report on Tuesday, May 28th. They issued an “outperform” rating and a $40.00 price target on the stock. Morgan Stanley initiated coverage on shares of TransMedics Group in a report on Tuesday, May 28th. They issued an “equal weight” rating on the stock. JPMorgan Chase & Co. initiated coverage on shares of TransMedics Group in a report on Tuesday, May 28th. They issued an “overweight” rating and a $34.00 price target on the stock. Finally, Canaccord Genuity initiated coverage on shares of TransMedics Group in a report on Tuesday, May 28th. They issued a “buy” rating and a $37.00 price target on the stock.
TransMedics Group stock opened at $26.50 on Monday. TransMedics Group has a twelve month low of $19.76 and a twelve month high of $31.54.
In other TransMedics Group news, Director Edwin M. Kania, Jr. bought 33,333 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $533,328.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
TransMedics Group Company Profile
TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.
Further Reading: What are the FAANG Stocks?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.